I-Mab Stock Price, News & Analysis

I-Mab (Nasdaq: IMAB) announced its plan to present preclinical data for its anti-C5aR monoclonal antibody, TJ210, at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting from November 9-14, 2020. The data aims to support TJ210's use as a monotherapy or in combination with anti-PD-1 therapies in cancer treatment. TJ210 is designed to inhibit pro-tumor cell recruitment in the tumor microenvironment, potentially enhancing immune response against cancer.

I-Mab (Nasdaq: IMAB) announced it will present findings from its U.S. phase 1 trial of lemzoparlimab (TJC4), a novel anti-CD47 monoclonal antibody, at the SITC 2020 annual meeting from November 9-14. The data will cover safety, pharmacokinetics, pharmacodynamics, receptor occupancy, and preliminary efficacy of the drug in treating relapsed or refractory malignancies. Lemzoparlimab aims to minimize the side effects commonly associated with similar therapies, marking a significant advancement in cancer treatments. The partnership with AbbVie is expected to enhance its development and commercialization efforts.

I-Mab (Nasdaq: IMAB) announced that the China Center for Drug Evaluation has approved the pivotal trial for eftansomatropin (TJ101) as a weekly treatment for pediatric growth hormone deficiency (PGHD). This marks a significant milestone for I-Mab and potential therapies for PGHD patients. Eftansomatropin, utilizing innovative hyFc® technology, aims to provide a safer and more effective alternative to daily injections. The phase 3 trial will compare its efficacy and safety against Norditropin, targeting a market where only 3.7% of 3.4 million pediatric patients currently receive treatment.

I-Mab (Nasdaq: IMAB) has received clearance from China's NMPA for initiating a phase 1 clinical trial of lemzoparlimab, an anti-CD47 monoclonal antibody, in patients with relapsed or refractory advanced lymphoma. The trial follows positive preliminary results from an ongoing phase 1 trial in the U.S., demonstrating safety and favorable pharmacokinetics with no severe hematologic adverse events. Additionally, a phase 1/2a trial in acute myeloid leukemia is underway. I-Mab has established a global partnership with AbbVie for the development and commercialization of lemzoparlimab, retaining rights for mainland China, Macau, and Hong Kong.

MorphoSys and I-Mab announced that the FDA has approved the Investigational New Drug (IND) application for MOR210/TJ210, a monoclonal antibody targeting C5aR1, aimed at treating relapsed or refractory advanced solid tumors. The Phase 1 trial will evaluate the drug's safety and efficacy, following promising preclinical results. This collaboration, initiated in November 2018, allows I-Mab exclusive rights for development in Greater China and South Korea, while MorphoSys retains rights elsewhere. The trial is set to start soon, marking a significant advancement in cancer treatment.

I-Mab (Nasdaq: IMAB), a clinical stage biopharmaceutical company, announced its participation in several September conferences. Key events include the Cantor Fitzgerald Virtual Global Healthcare Conference on September 15, Jefferies Virtual Asia Forum on September 16, and the ICBCI Virtual ADR New Economy Conference on September 18, among others. Notable presenters include Dr. Jingwu Zang and Dr. Joan Huaqiong Shen, providing insights into the company's innovations in immuno-oncology and autoimmune diseases. I-Mab is focused on transitioning to a fully integrated global biopharmaceutical company.

I-Mab (Nasdaq: IMAB) announced a private placement to raise approximately US$418 million led by Hillhouse Capital Group, involving the sale of 29,133,502 ordinary shares at US$33 per ADS, a 2.9% premium to the 30-day VWAP. The deal includes warrants for an additional US$104.5 million if exercised. Funds will support ongoing clinical programs and commercialization efforts in China. The press release also details a global partnership for the development of lemzoparlimab, an anti-CD47 antibody for cancer treatment.

AbbVie and I-Mab have entered a global collaboration for the development and commercialization of lemzoparlimab, an innovative anti-CD47 monoclonal antibody aimed at treating various cancers. AbbVie will pay I-Mab USD 200 million upfront, with potential milestone payments of up to USD 1.74 billion. Results from a recent phase 1 clinical trial indicate that lemzoparlimab is well-tolerated, showing promising safety profiles without dose-limiting toxicities. The partnership aims to accelerate clinical trials and commercialization efforts worldwide.

I-Mab (Nasdaq: IMAB) reported significant developments in its pipeline, particularly highlighting positive preliminary results for lemzoparlimab (TJC4) in cancer trials, demonstrating strong safety and pharmacokinetics. The company is also advancing plonmarlimab (TJM2) in a COVID-19 study and expects critical updates, including IND approval for eftansomatropin (TJ101) and data readouts from various ongoing trials in H2 2020. Financially, I-Mab's cash reserves have increased to RMB1.6 billion, though it reported a net loss of RMB582.9 million for the first half of 2020, a decrease from the previous year.